Literature DB >> 28940049

The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings.

Helen Tremlett1, Emmanuelle Waubant2.   

Abstract

Pediatric multiple sclerosis (MS) is a chronic, life-long neurological condition associated with inflammation and degeneration in the brain and spinal cord. Fortunately, < 5% of people with MS have their onset in childhood years. However, studying these very-early-onset cases of MS offers key advantages. In particular, with fewer years lived, children have had a limited range of exposures, potentially enhancing our ability to identify what might cause MS. Further, as the actual timing of the biological MS onset is unknown, the possibility to study these children much closer to the real onset of disease is far greater than in the typical adult with MS. Whether MS (in children or adults) can be prevented is unknown and the available drugs are only modestly effective in modifying the disease course and are not without risk. Emerging evidence is providing insight into the gut microbiota's potential role in triggering and shaping neurological conditions such as MS. The limited number of studies in humans with MS and absence of prior work in pediatric MS motivated the following 3 fundamental questions, addressed in 2 cross-sectional and 1 longitudinal investigation in children with and without MS: 1) Does the gut microbiota composition differ between children with and without MS? 2) Is there an association between the gut microbiota and host immune markers in children with and without MS? 3) Is the gut microbiota associated with the future risk of a MS relapse?

Entities:  

Keywords:  16S rRNA; Case–control; Cross-sectional; Disease-modifying drugs; Longitudinal; Metagenomics; Microbiome; Microbiota; Multiple sclerosis; Pediatric; Relapse risk; Relapsing-remitting

Mesh:

Substances:

Year:  2018        PMID: 28940049      PMCID: PMC5794692          DOI: 10.1007/s13311-017-0574-3

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  45 in total

Review 1.  Glutathione in multiple sclerosis: more than just an antioxidant?

Authors:  Andreia N Carvalho; Jamie L Lim; Philip G Nijland; Maarten E Witte; Jack Van Horssen
Journal:  Mult Scler       Date:  2014-05-19       Impact factor: 6.312

Review 2.  Circulating immune cells in multiple sclerosis.

Authors:  A P Jones; A G Kermode; R M Lucas; W M Carroll; D Nolan; P H Hart
Journal:  Clin Exp Immunol       Date:  2016-11-02       Impact factor: 4.330

3.  Gut microbiota in multiple sclerosis: possible influence of immunomodulators.

Authors:  Brandi L Cantarel; Emmanuelle Waubant; Christel Chehoud; Justin Kuczynski; Todd Z DeSantis; Janet Warrington; Arun Venkatesan; Claire M Fraser; Ellen M Mowry
Journal:  J Investig Med       Date:  2015-06       Impact factor: 2.895

4.  Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis.

Authors:  Jennifer S Graves; Tanuja Chitnis; Bianca Weinstock-Guttman; Jennifer Rubin; Aaron S Zelikovitch; Bardia Nourbakhsh; Timothy Simmons; Michael Waltz; T Charles Casper; Emmanuelle Waubant
Journal:  Pediatrics       Date:  2017-04       Impact factor: 7.124

5.  Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.

Authors:  José M A Wijnands; Elaine Kingwell; Feng Zhu; Yinshan Zhao; Tanja Högg; Karen Stadnyk; Okechukwu Ekuma; Xinya Lu; Charity Evans; John D Fisk; Ruth Ann Marrie; Helen Tremlett
Journal:  Lancet Neurol       Date:  2017-04-20       Impact factor: 44.182

6.  Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases.

Authors:  Julien Loubinoux; Jean-Pierre Bronowicki; Ines A C Pereira; Jean-Louis Mougenel; Alain E Faou
Journal:  FEMS Microbiol Ecol       Date:  2002-05-01       Impact factor: 4.194

7.  Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease.

Authors:  Wei Wang; Liping Chen; Rui Zhou; Xiaobing Wang; Lu Song; Sha Huang; Ge Wang; Bing Xia
Journal:  J Clin Microbiol       Date:  2013-11-13       Impact factor: 5.948

8.  Gut microbiota composition and relapse risk in pediatric MS: A pilot study.

Authors:  Helen Tremlett; Douglas W Fadrosh; Ali A Faruqi; Janace Hart; Shelly Roalstad; Jennifer Graves; Susan Lynch; Emmanuelle Waubant
Journal:  J Neurol Sci       Date:  2016-02-20       Impact factor: 3.181

Review 9.  Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

Authors:  V Wee Yong
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

10.  Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization.

Authors:  Raffaella Di Cagno; Maria De Angelis; Ilaria De Pasquale; Maurice Ndagijimana; Pamela Vernocchi; Patrizia Ricciuti; Francesca Gagliardi; Luca Laghi; Carmine Crecchio; Maria Elisabetta Guerzoni; Marco Gobbetti; Ruggiero Francavilla
Journal:  BMC Microbiol       Date:  2011-10-04       Impact factor: 3.605

View more
  8 in total

1.  The Microbiome and Neurologic Disease: Past and Future of a 2-Way Interaction.

Authors:  Javier Ochoa-Repáraz; Lloyd H Kasper
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

Review 2.  Unravelling the potential of gut microbiota in sustaining brain health and their current prospective towards development of neurotherapeutics.

Authors:  Ankita Banerjee; Lilesh Kumar Pradhan; Santosh Chauhan; Pradyumna Kumar Sahoo; Kautilya Kumar Jena; Nishant Ranjan Chauhan; Saroj Kumar Das
Journal:  Arch Microbiol       Date:  2021-03-24       Impact factor: 2.552

3.  Extra-Virgin Olive Oil Modifies the Changes Induced in Non-Nervous Organs and Tissues by Experimental Autoimmune Encephalomyelitis Models.

Authors:  Cristina Conde; Begoña M Escribano; Evelio Luque; Montserrat Feijóo; Javier Caballero-Villarraso; Manuel E Valdelvira; Juan J Ochoa-Sepúlveda; Rafael Lillo; Elier Paz; Abel Santamaría; Eduardo Agüera; Isaac Túnez
Journal:  Nutrients       Date:  2019-10-14       Impact factor: 5.717

Review 4.  Regulation of common neurological disorders by gut microbial metabolites.

Authors:  Jeongho Park; Chang H Kim
Journal:  Exp Mol Med       Date:  2021-12-02       Impact factor: 8.718

5.  Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire).

Authors:  Silvy Pilotto; Jessica Gencarelli; Stefania Bova; Leonardo Gerosa; Damiano Baroncini; Sara Olivotto; Enrico Alfei; Mauro Zaffaroni; Agnese Suppiej; Eleonora Cocco; Maria Trojano; Maria Pia Amato; Sandra D'Alfonso; Filippo Martinelli-Boneschi; Emmanuelle Waubant; Angelo Ghezzi; Roberto Bergamaschi; Maura Pugliatti
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-12-01

Review 6.  Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis.

Authors:  Hammad Ullah; Olga Tovchiga; Maria Daglia; Haroon Khan
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

7.  Long-Term Provision of Acidified Drinking Water Fails to Influence Autoimmune Diabetes and Encephalomyelitis.

Authors:  Sundararajan Jayaraman; Arathi Jayaraman
Journal:  J Diabetes Res       Date:  2018-06-21       Impact factor: 4.011

8.  Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course.

Authors:  Bardia Nourbakhsh; Pavan Bhargava; Helen Tremlett; Janace Hart; Jennifer Graves; Emmanuelle Waubant
Journal:  Ann Clin Transl Neurol       Date:  2018-09-27       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.